nodes	percent_of_prediction	percent_of_DWPC	metapath
Methylnaltrexone—CYP2D6—Bicalutamide—prostate cancer	0.182	0.505	CbGbCtD
Methylnaltrexone—CYP2D6—Abiraterone—prostate cancer	0.151	0.418	CbGbCtD
Methylnaltrexone—CYP2D6—Doxorubicin—prostate cancer	0.0279	0.0773	CbGbCtD
Methylnaltrexone—Gastrointestinal perforation—Docetaxel—prostate cancer	0.0091	0.0215	CcSEcCtD
Methylnaltrexone—Gastrointestinal perforation—Capecitabine—prostate cancer	0.00881	0.0208	CcSEcCtD
Methylnaltrexone—Injection site reaction—Degarelix—prostate cancer	0.00823	0.0194	CcSEcCtD
Methylnaltrexone—Injection site reaction—Bicalutamide—prostate cancer	0.00665	0.0157	CcSEcCtD
Methylnaltrexone—Redness—Estradiol—prostate cancer	0.00546	0.0129	CcSEcCtD
Methylnaltrexone—Injection site reaction—Goserelin—prostate cancer	0.00463	0.0109	CcSEcCtD
Methylnaltrexone—Flatulence—Estramustine—prostate cancer	0.0045	0.0106	CcSEcCtD
Methylnaltrexone—Flatulence—Estrone—prostate cancer	0.0043	0.0101	CcSEcCtD
Methylnaltrexone—Naloxone—TLR4—prostate cancer	0.00412	0.251	CrCbGaD
Methylnaltrexone—Erythema—Flutamide—prostate cancer	0.00403	0.0095	CcSEcCtD
Methylnaltrexone—Flatulence—Estradiol valerate/Dienogest—prostate cancer	0.00375	0.00884	CcSEcCtD
Methylnaltrexone—Unspecified disorder of skin and subcutaneous tissue—Abiraterone—prostate cancer	0.00375	0.00884	CcSEcCtD
Methylnaltrexone—Oedema—Estramustine—prostate cancer	0.00373	0.00878	CcSEcCtD
Methylnaltrexone—Oedema—Abiraterone—prostate cancer	0.00362	0.00853	CcSEcCtD
Methylnaltrexone—Erythema—Degarelix—prostate cancer	0.00362	0.00853	CcSEcCtD
Methylnaltrexone—Oedema—Estrone—prostate cancer	0.00356	0.00839	CcSEcCtD
Methylnaltrexone—Redness—Docetaxel—prostate cancer	0.00352	0.0083	CcSEcCtD
Methylnaltrexone—Skin disorder—Abiraterone—prostate cancer	0.00352	0.00828	CcSEcCtD
Methylnaltrexone—Unspecified disorder of skin and subcutaneous tissue—Flutamide—prostate cancer	0.00341	0.00804	CcSEcCtD
Methylnaltrexone—Erythema—Cabazitaxel—prostate cancer	0.00341	0.00803	CcSEcCtD
Methylnaltrexone—Oedema—Nilutamide—prostate cancer	0.00331	0.00779	CcSEcCtD
Methylnaltrexone—Oedema—Flutamide—prostate cancer	0.00329	0.00776	CcSEcCtD
Methylnaltrexone—Skin disorder—Flutamide—prostate cancer	0.0032	0.00753	CcSEcCtD
Methylnaltrexone—Hyperhidrosis—Nilutamide—prostate cancer	0.0032	0.00753	CcSEcCtD
Methylnaltrexone—Gastrointestinal disorder—Abiraterone—prostate cancer	0.00312	0.00736	CcSEcCtD
Methylnaltrexone—Oedema—Estradiol valerate/Dienogest—prostate cancer	0.00311	0.00732	CcSEcCtD
Methylnaltrexone—Unspecified disorder of skin and subcutaneous tissue—Degarelix—prostate cancer	0.00306	0.00721	CcSEcCtD
Methylnaltrexone—Nervous system disorder—Estradiol valerate/Dienogest—prostate cancer	0.00305	0.00718	CcSEcCtD
Methylnaltrexone—Pain—Estrone—prostate cancer	0.00304	0.00717	CcSEcCtD
Methylnaltrexone—Nervous system disorder—Degarelix—prostate cancer	0.0029	0.00683	CcSEcCtD
Methylnaltrexone—Unspecified disorder of skin and subcutaneous tissue—Cabazitaxel—prostate cancer	0.00288	0.00679	CcSEcCtD
Methylnaltrexone—Flatulence—Bicalutamide—prostate cancer	0.00288	0.00679	CcSEcCtD
Methylnaltrexone—Skin disorder—Degarelix—prostate cancer	0.00287	0.00676	CcSEcCtD
Methylnaltrexone—Hyperhidrosis—Degarelix—prostate cancer	0.00286	0.00673	CcSEcCtD
Methylnaltrexone—Gastrointestinal disorder—Nilutamide—prostate cancer	0.00285	0.00673	CcSEcCtD
Methylnaltrexone—Pain—Nilutamide—prostate cancer	0.00283	0.00666	CcSEcCtD
Methylnaltrexone—Abdominal pain—Estrone—prostate cancer	0.00281	0.00663	CcSEcCtD
Methylnaltrexone—Oedema—Cabazitaxel—prostate cancer	0.00278	0.00656	CcSEcCtD
Methylnaltrexone—Nervous system disorder—Cabazitaxel—prostate cancer	0.00273	0.00643	CcSEcCtD
Methylnaltrexone—Gastrointestinal pain—Nilutamide—prostate cancer	0.0027	0.00637	CcSEcCtD
Methylnaltrexone—Skin disorder—Cabazitaxel—prostate cancer	0.0027	0.00637	CcSEcCtD
Methylnaltrexone—Gastrointestinal disorder—Estradiol valerate/Dienogest—prostate cancer	0.00268	0.00632	CcSEcCtD
Methylnaltrexone—Pain—Estradiol valerate/Dienogest—prostate cancer	0.00266	0.00626	CcSEcCtD
Methylnaltrexone—Abdominal pain—Nilutamide—prostate cancer	0.00261	0.00616	CcSEcCtD
Methylnaltrexone—Gastrointestinal disorder—Degarelix—prostate cancer	0.00255	0.00601	CcSEcCtD
Methylnaltrexone—Diarrhoea—Estramustine—prostate cancer	0.00255	0.00601	CcSEcCtD
Methylnaltrexone—Gastrointestinal pain—Estradiol valerate/Dienogest—prostate cancer	0.00254	0.00599	CcSEcCtD
Methylnaltrexone—Pain—Degarelix—prostate cancer	0.00253	0.00595	CcSEcCtD
Methylnaltrexone—Diarrhoea—Abiraterone—prostate cancer	0.00248	0.00584	CcSEcCtD
Methylnaltrexone—Unspecified disorder of skin and subcutaneous tissue—Bicalutamide—prostate cancer	0.00247	0.00583	CcSEcCtD
Methylnaltrexone—Abdominal pain—Estradiol valerate/Dienogest—prostate cancer	0.00246	0.00579	CcSEcCtD
Methylnaltrexone—Gastrointestinal pain—Degarelix—prostate cancer	0.00242	0.00569	CcSEcCtD
Methylnaltrexone—Gastrointestinal disorder—Cabazitaxel—prostate cancer	0.0024	0.00566	CcSEcCtD
Methylnaltrexone—Oedema—Bicalutamide—prostate cancer	0.00239	0.00562	CcSEcCtD
Methylnaltrexone—Pain—Cabazitaxel—prostate cancer	0.00238	0.00561	CcSEcCtD
Methylnaltrexone—Redness—Epirubicin—prostate cancer	0.00237	0.0056	CcSEcCtD
Methylnaltrexone—Vomiting—Estramustine—prostate cancer	0.00237	0.00558	CcSEcCtD
Methylnaltrexone—Injection site reaction—Docetaxel—prostate cancer	0.00236	0.00557	CcSEcCtD
Methylnaltrexone—Dizziness—Estrone—prostate cancer	0.00235	0.00555	CcSEcCtD
Methylnaltrexone—Nervous system disorder—Bicalutamide—prostate cancer	0.00234	0.00552	CcSEcCtD
Methylnaltrexone—Abdominal pain—Degarelix—prostate cancer	0.00233	0.0055	CcSEcCtD
Methylnaltrexone—Skin disorder—Bicalutamide—prostate cancer	0.00232	0.00546	CcSEcCtD
Methylnaltrexone—Hyperhidrosis—Bicalutamide—prostate cancer	0.00231	0.00544	CcSEcCtD
Methylnaltrexone—Vomiting—Abiraterone—prostate cancer	0.0023	0.00542	CcSEcCtD
Methylnaltrexone—Injection site reaction—Capecitabine—prostate cancer	0.00229	0.00539	CcSEcCtD
Methylnaltrexone—Gastrointestinal pain—Cabazitaxel—prostate cancer	0.00228	0.00536	CcSEcCtD
Methylnaltrexone—Vomiting—Estrone—prostate cancer	0.00226	0.00533	CcSEcCtD
Methylnaltrexone—Diarrhoea—Nilutamide—prostate cancer	0.00226	0.00533	CcSEcCtD
Methylnaltrexone—Diarrhoea—Flutamide—prostate cancer	0.00225	0.00531	CcSEcCtD
Methylnaltrexone—Nausea—Estramustine—prostate cancer	0.00221	0.00522	CcSEcCtD
Methylnaltrexone—Abdominal pain—Cabazitaxel—prostate cancer	0.0022	0.00518	CcSEcCtD
Methylnaltrexone—Redness—Doxorubicin—prostate cancer	0.0022	0.00518	CcSEcCtD
Methylnaltrexone—Dizziness—Nilutamide—prostate cancer	0.00219	0.00515	CcSEcCtD
Methylnaltrexone—Dizziness—Flutamide—prostate cancer	0.00218	0.00513	CcSEcCtD
Methylnaltrexone—Nausea—Estrone—prostate cancer	0.00211	0.00498	CcSEcCtD
Methylnaltrexone—Vomiting—Nilutamide—prostate cancer	0.0021	0.00495	CcSEcCtD
Methylnaltrexone—Vomiting—Flutamide—prostate cancer	0.00209	0.00493	CcSEcCtD
Methylnaltrexone—Unspecified disorder of skin and subcutaneous tissue—Ethinyl Estradiol—prostate cancer	0.00209	0.00493	CcSEcCtD
Methylnaltrexone—Buprenorphine—CYP2C18—prostate cancer	0.00209	0.127	CrCbGaD
Methylnaltrexone—Gastrointestinal disorder—Bicalutamide—prostate cancer	0.00206	0.00486	CcSEcCtD
Methylnaltrexone—Dizziness—Estradiol valerate/Dienogest—prostate cancer	0.00205	0.00484	CcSEcCtD
Methylnaltrexone—Pain—Bicalutamide—prostate cancer	0.00204	0.00481	CcSEcCtD
Methylnaltrexone—Erythema—Goserelin—prostate cancer	0.00203	0.00479	CcSEcCtD
Methylnaltrexone—Diarrhoea—Degarelix—prostate cancer	0.00202	0.00476	CcSEcCtD
Methylnaltrexone—Oedema—Ethinyl Estradiol—prostate cancer	0.00202	0.00475	CcSEcCtD
Methylnaltrexone—Erythema—Conjugated Estrogens—prostate cancer	0.00202	0.00475	CcSEcCtD
Methylnaltrexone—Flatulence—Goserelin—prostate cancer	0.002	0.00472	CcSEcCtD
Methylnaltrexone—Flatulence—Conjugated Estrogens—prostate cancer	0.00199	0.00468	CcSEcCtD
Methylnaltrexone—Nervous system disorder—Ethinyl Estradiol—prostate cancer	0.00198	0.00466	CcSEcCtD
Methylnaltrexone—Stinging—Epirubicin—prostate cancer	0.00198	0.00466	CcSEcCtD
Methylnaltrexone—Vomiting—Estradiol valerate/Dienogest—prostate cancer	0.00198	0.00465	CcSEcCtD
Methylnaltrexone—Nausea—Nilutamide—prostate cancer	0.00196	0.00463	CcSEcCtD
Methylnaltrexone—Skin disorder—Ethinyl Estradiol—prostate cancer	0.00196	0.00462	CcSEcCtD
Methylnaltrexone—Nausea—Flutamide—prostate cancer	0.00196	0.00461	CcSEcCtD
Methylnaltrexone—Dizziness—Degarelix—prostate cancer	0.00195	0.0046	CcSEcCtD
Methylnaltrexone—Gastrointestinal pain—Bicalutamide—prostate cancer	0.00195	0.0046	CcSEcCtD
Methylnaltrexone—Diarrhoea—Cabazitaxel—prostate cancer	0.0019	0.00449	CcSEcCtD
Methylnaltrexone—Abdominal pain—Bicalutamide—prostate cancer	0.00189	0.00445	CcSEcCtD
Methylnaltrexone—Vomiting—Degarelix—prostate cancer	0.00188	0.00443	CcSEcCtD
Methylnaltrexone—Nausea—Estradiol valerate/Dienogest—prostate cancer	0.00185	0.00435	CcSEcCtD
Methylnaltrexone—Dizziness—Cabazitaxel—prostate cancer	0.00184	0.00434	CcSEcCtD
Methylnaltrexone—Stinging—Doxorubicin—prostate cancer	0.00183	0.00431	CcSEcCtD
Methylnaltrexone—Vomiting—Cabazitaxel—prostate cancer	0.00177	0.00417	CcSEcCtD
Methylnaltrexone—Nausea—Degarelix—prostate cancer	0.00175	0.00413	CcSEcCtD
Methylnaltrexone—Gastrointestinal disorder—Ethinyl Estradiol—prostate cancer	0.00174	0.0041	CcSEcCtD
Methylnaltrexone—Unspecified disorder of skin and subcutaneous tissue—Goserelin—prostate cancer	0.00172	0.00405	CcSEcCtD
Methylnaltrexone—Unspecified disorder of skin and subcutaneous tissue—Conjugated Estrogens—prostate cancer	0.0017	0.00402	CcSEcCtD
Methylnaltrexone—Oedema—Goserelin—prostate cancer	0.00166	0.00391	CcSEcCtD
Methylnaltrexone—Nausea—Cabazitaxel—prostate cancer	0.00165	0.00389	CcSEcCtD
Methylnaltrexone—Gastrointestinal pain—Ethinyl Estradiol—prostate cancer	0.00165	0.00389	CcSEcCtD
Methylnaltrexone—Oedema—Conjugated Estrogens—prostate cancer	0.00164	0.00388	CcSEcCtD
Methylnaltrexone—Diarrhoea—Bicalutamide—prostate cancer	0.00163	0.00385	CcSEcCtD
Methylnaltrexone—Nervous system disorder—Goserelin—prostate cancer	0.00163	0.00384	CcSEcCtD
Methylnaltrexone—Nervous system disorder—Conjugated Estrogens—prostate cancer	0.00161	0.0038	CcSEcCtD
Methylnaltrexone—Erythema—Estradiol—prostate cancer	0.00161	0.0038	CcSEcCtD
Methylnaltrexone—Skin disorder—Goserelin—prostate cancer	0.00161	0.0038	CcSEcCtD
Methylnaltrexone—Hyperhidrosis—Goserelin—prostate cancer	0.00161	0.00378	CcSEcCtD
Methylnaltrexone—Skin disorder—Conjugated Estrogens—prostate cancer	0.0016	0.00376	CcSEcCtD
Methylnaltrexone—Abdominal pain—Ethinyl Estradiol—prostate cancer	0.00159	0.00376	CcSEcCtD
Methylnaltrexone—Injection site reaction—Epirubicin—prostate cancer	0.00159	0.00375	CcSEcCtD
Methylnaltrexone—Hyperhidrosis—Conjugated Estrogens—prostate cancer	0.00159	0.00375	CcSEcCtD
Methylnaltrexone—Flatulence—Estradiol—prostate cancer	0.00159	0.00375	CcSEcCtD
Methylnaltrexone—Dizziness—Bicalutamide—prostate cancer	0.00158	0.00372	CcSEcCtD
Methylnaltrexone—Vomiting—Bicalutamide—prostate cancer	0.00152	0.00358	CcSEcCtD
Methylnaltrexone—Erythema—Mitoxantrone—prostate cancer	0.0015	0.00354	CcSEcCtD
Methylnaltrexone—Oxycodone—CYP3A5—prostate cancer	0.00149	0.0908	CrCbGaD
Methylnaltrexone—Injection site reaction—Doxorubicin—prostate cancer	0.00147	0.00347	CcSEcCtD
Methylnaltrexone—Gastrointestinal disorder—Conjugated Estrogens—prostate cancer	0.00142	0.00335	CcSEcCtD
Methylnaltrexone—Pain—Goserelin—prostate cancer	0.00142	0.00335	CcSEcCtD
Methylnaltrexone—Nausea—Bicalutamide—prostate cancer	0.00142	0.00334	CcSEcCtD
Methylnaltrexone—Pain—Conjugated Estrogens—prostate cancer	0.00141	0.00331	CcSEcCtD
Methylnaltrexone—Diarrhoea—Ethinyl Estradiol—prostate cancer	0.00138	0.00325	CcSEcCtD
Methylnaltrexone—Buprenorphine—CYP3A5—prostate cancer	0.00137	0.0836	CrCbGaD
Methylnaltrexone—Unspecified disorder of skin and subcutaneous tissue—Estradiol—prostate cancer	0.00136	0.00321	CcSEcCtD
Methylnaltrexone—Gastrointestinal pain—Goserelin—prostate cancer	0.00136	0.0032	CcSEcCtD
Methylnaltrexone—Gastrointestinal pain—Conjugated Estrogens—prostate cancer	0.00134	0.00317	CcSEcCtD
Methylnaltrexone—Dizziness—Ethinyl Estradiol—prostate cancer	0.00133	0.00314	CcSEcCtD
Methylnaltrexone—Buprenorphine—CYP2A6—prostate cancer	0.00133	0.0809	CrCbGaD
Methylnaltrexone—Oedema—Estradiol—prostate cancer	0.00132	0.0031	CcSEcCtD
Methylnaltrexone—Abdominal pain—Goserelin—prostate cancer	0.00131	0.00309	CcSEcCtD
Methylnaltrexone—Abdominal pain—Conjugated Estrogens—prostate cancer	0.0013	0.00306	CcSEcCtD
Methylnaltrexone—Nervous system disorder—Estradiol—prostate cancer	0.00129	0.00304	CcSEcCtD
Methylnaltrexone—Vomiting—Ethinyl Estradiol—prostate cancer	0.00128	0.00302	CcSEcCtD
Methylnaltrexone—Skin disorder—Estradiol—prostate cancer	0.00128	0.00301	CcSEcCtD
Methylnaltrexone—Hyperhidrosis—Estradiol—prostate cancer	0.00127	0.003	CcSEcCtD
Methylnaltrexone—Oedema—Mitoxantrone—prostate cancer	0.00123	0.00289	CcSEcCtD
Methylnaltrexone—Nausea—Ethinyl Estradiol—prostate cancer	0.0012	0.00282	CcSEcCtD
Methylnaltrexone—Skin disorder—Mitoxantrone—prostate cancer	0.00119	0.00281	CcSEcCtD
Methylnaltrexone—Hyperhidrosis—Mitoxantrone—prostate cancer	0.00119	0.00279	CcSEcCtD
Methylnaltrexone—Naloxone—ESR1—prostate cancer	0.00116	0.0704	CrCbGaD
Methylnaltrexone—Gastrointestinal disorder—Estradiol—prostate cancer	0.00114	0.00268	CcSEcCtD
Methylnaltrexone—Diarrhoea—Goserelin—prostate cancer	0.00114	0.00268	CcSEcCtD
Methylnaltrexone—Pain—Estradiol—prostate cancer	0.00113	0.00265	CcSEcCtD
Methylnaltrexone—Diarrhoea—Conjugated Estrogens—prostate cancer	0.00113	0.00265	CcSEcCtD
Methylnaltrexone—Dizziness—Goserelin—prostate cancer	0.0011	0.00259	CcSEcCtD
Methylnaltrexone—Dizziness—Conjugated Estrogens—prostate cancer	0.00109	0.00256	CcSEcCtD
Methylnaltrexone—Gastrointestinal pain—Estradiol—prostate cancer	0.00108	0.00254	CcSEcCtD
Methylnaltrexone—Unspecified disorder of skin and subcutaneous tissue—Etoposide—prostate cancer	0.00106	0.00249	CcSEcCtD
Methylnaltrexone—Vomiting—Goserelin—prostate cancer	0.00106	0.00249	CcSEcCtD
Methylnaltrexone—Pain—Mitoxantrone—prostate cancer	0.00105	0.00247	CcSEcCtD
Methylnaltrexone—Vomiting—Conjugated Estrogens—prostate cancer	0.00105	0.00246	CcSEcCtD
Methylnaltrexone—Abdominal pain—Estradiol—prostate cancer	0.00104	0.00245	CcSEcCtD
Methylnaltrexone—Erythema—Docetaxel—prostate cancer	0.00104	0.00245	CcSEcCtD
Methylnaltrexone—Erythema—Capecitabine—prostate cancer	0.00101	0.00237	CcSEcCtD
Methylnaltrexone—Gastrointestinal pain—Mitoxantrone—prostate cancer	0.001	0.00236	CcSEcCtD
Methylnaltrexone—Flatulence—Capecitabine—prostate cancer	0.000991	0.00234	CcSEcCtD
Methylnaltrexone—Skin disorder—Etoposide—prostate cancer	0.000991	0.00234	CcSEcCtD
Methylnaltrexone—Nausea—Goserelin—prostate cancer	0.000986	0.00232	CcSEcCtD
Methylnaltrexone—Hyperhidrosis—Etoposide—prostate cancer	0.000986	0.00232	CcSEcCtD
Methylnaltrexone—Nausea—Conjugated Estrogens—prostate cancer	0.000977	0.0023	CcSEcCtD
Methylnaltrexone—Abdominal pain—Mitoxantrone—prostate cancer	0.000969	0.00228	CcSEcCtD
Methylnaltrexone—Buprenorphine—CYP2C19—prostate cancer	0.000935	0.0569	CrCbGaD
Methylnaltrexone—Diarrhoea—Estradiol—prostate cancer	0.000901	0.00212	CcSEcCtD
Methylnaltrexone—Erythema—Prednisone—prostate cancer	0.000896	0.00211	CcSEcCtD
Methylnaltrexone—Gastrointestinal disorder—Etoposide—prostate cancer	0.000881	0.00208	CcSEcCtD
Methylnaltrexone—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—prostate cancer	0.000878	0.00207	CcSEcCtD
Methylnaltrexone—Pain—Etoposide—prostate cancer	0.000872	0.00206	CcSEcCtD
Methylnaltrexone—Dizziness—Estradiol—prostate cancer	0.00087	0.00205	CcSEcCtD
Methylnaltrexone—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—prostate cancer	0.00085	0.002	CcSEcCtD
Methylnaltrexone—Oedema—Docetaxel—prostate cancer	0.000848	0.002	CcSEcCtD
Methylnaltrexone—Diarrhoea—Mitoxantrone—prostate cancer	0.000839	0.00198	CcSEcCtD
Methylnaltrexone—Vomiting—Estradiol—prostate cancer	0.000837	0.00197	CcSEcCtD
Methylnaltrexone—Gastrointestinal pain—Etoposide—prostate cancer	0.000834	0.00197	CcSEcCtD
Methylnaltrexone—Nervous system disorder—Docetaxel—prostate cancer	0.000831	0.00196	CcSEcCtD
Methylnaltrexone—Skin disorder—Docetaxel—prostate cancer	0.000823	0.00194	CcSEcCtD
Methylnaltrexone—Oedema—Capecitabine—prostate cancer	0.000821	0.00193	CcSEcCtD
Methylnaltrexone—Oxymorphone—CYP3A4—prostate cancer	0.000809	0.0493	CrCbGaD
Methylnaltrexone—Abdominal pain—Etoposide—prostate cancer	0.000806	0.0019	CcSEcCtD
Methylnaltrexone—Nervous system disorder—Capecitabine—prostate cancer	0.000805	0.0019	CcSEcCtD
Methylnaltrexone—Skin disorder—Capecitabine—prostate cancer	0.000797	0.00188	CcSEcCtD
Methylnaltrexone—Hyperhidrosis—Capecitabine—prostate cancer	0.000793	0.00187	CcSEcCtD
Methylnaltrexone—Nausea—Estradiol—prostate cancer	0.000782	0.00184	CcSEcCtD
Methylnaltrexone—Vomiting—Mitoxantrone—prostate cancer	0.00078	0.00184	CcSEcCtD
Methylnaltrexone—Unspecified disorder of skin and subcutaneous tissue—Prednisone—prostate cancer	0.000757	0.00178	CcSEcCtD
Methylnaltrexone—Gastrointestinal disorder—Docetaxel—prostate cancer	0.000732	0.00172	CcSEcCtD
Methylnaltrexone—Oedema—Prednisone—prostate cancer	0.000731	0.00172	CcSEcCtD
Methylnaltrexone—Nausea—Mitoxantrone—prostate cancer	0.000728	0.00172	CcSEcCtD
Methylnaltrexone—Pain—Docetaxel—prostate cancer	0.000725	0.00171	CcSEcCtD
Methylnaltrexone—Nervous system disorder—Prednisone—prostate cancer	0.000717	0.00169	CcSEcCtD
Methylnaltrexone—Skin disorder—Prednisone—prostate cancer	0.00071	0.00167	CcSEcCtD
Methylnaltrexone—Gastrointestinal disorder—Capecitabine—prostate cancer	0.000709	0.00167	CcSEcCtD
Methylnaltrexone—Hydrocodone—CYP3A4—prostate cancer	0.000707	0.043	CrCbGaD
Methylnaltrexone—Hyperhidrosis—Prednisone—prostate cancer	0.000707	0.00167	CcSEcCtD
Methylnaltrexone—Pain—Capecitabine—prostate cancer	0.000702	0.00165	CcSEcCtD
Methylnaltrexone—Erythema—Epirubicin—prostate cancer	0.000701	0.00165	CcSEcCtD
Methylnaltrexone—Diarrhoea—Etoposide—prostate cancer	0.000698	0.00164	CcSEcCtD
Methylnaltrexone—Gastrointestinal pain—Docetaxel—prostate cancer	0.000693	0.00163	CcSEcCtD
Methylnaltrexone—Flatulence—Epirubicin—prostate cancer	0.00069	0.00163	CcSEcCtD
Methylnaltrexone—Dizziness—Etoposide—prostate cancer	0.000675	0.00159	CcSEcCtD
Methylnaltrexone—Gastrointestinal pain—Capecitabine—prostate cancer	0.000671	0.00158	CcSEcCtD
Methylnaltrexone—Abdominal pain—Docetaxel—prostate cancer	0.00067	0.00158	CcSEcCtD
Methylnaltrexone—Abdominal pain—Capecitabine—prostate cancer	0.000649	0.00153	CcSEcCtD
Methylnaltrexone—Vomiting—Etoposide—prostate cancer	0.000649	0.00153	CcSEcCtD
Methylnaltrexone—Erythema—Doxorubicin—prostate cancer	0.000648	0.00153	CcSEcCtD
Methylnaltrexone—Oxycodone—CYP3A4—prostate cancer	0.000645	0.0393	CrCbGaD
Methylnaltrexone—Flatulence—Doxorubicin—prostate cancer	0.000639	0.00151	CcSEcCtD
Methylnaltrexone—Nausea—Etoposide—prostate cancer	0.000606	0.00143	CcSEcCtD
Methylnaltrexone—Gastrointestinal pain—Prednisone—prostate cancer	0.000598	0.00141	CcSEcCtD
Methylnaltrexone—Buprenorphine—CYP3A4—prostate cancer	0.000595	0.0362	CrCbGaD
Methylnaltrexone—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—prostate cancer	0.000592	0.0014	CcSEcCtD
Methylnaltrexone—Naloxone—CYP3A4—prostate cancer	0.00059	0.0359	CrCbGaD
Methylnaltrexone—Hydromorphone—CYP3A4—prostate cancer	0.000586	0.0357	CrCbGaD
Methylnaltrexone—Diarrhoea—Docetaxel—prostate cancer	0.00058	0.00137	CcSEcCtD
Methylnaltrexone—Abdominal pain—Prednisone—prostate cancer	0.000578	0.00136	CcSEcCtD
Methylnaltrexone—Oedema—Epirubicin—prostate cancer	0.000572	0.00135	CcSEcCtD
Methylnaltrexone—Diarrhoea—Capecitabine—prostate cancer	0.000562	0.00132	CcSEcCtD
Methylnaltrexone—Nervous system disorder—Epirubicin—prostate cancer	0.000561	0.00132	CcSEcCtD
Methylnaltrexone—Dizziness—Docetaxel—prostate cancer	0.000561	0.00132	CcSEcCtD
Methylnaltrexone—Skin disorder—Epirubicin—prostate cancer	0.000555	0.00131	CcSEcCtD
Methylnaltrexone—Hyperhidrosis—Epirubicin—prostate cancer	0.000553	0.0013	CcSEcCtD
Methylnaltrexone—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—prostate cancer	0.000548	0.00129	CcSEcCtD
Methylnaltrexone—Dizziness—Capecitabine—prostate cancer	0.000543	0.00128	CcSEcCtD
Methylnaltrexone—Vomiting—Docetaxel—prostate cancer	0.000539	0.00127	CcSEcCtD
Methylnaltrexone—Oedema—Doxorubicin—prostate cancer	0.000529	0.00125	CcSEcCtD
Methylnaltrexone—Vomiting—Capecitabine—prostate cancer	0.000522	0.00123	CcSEcCtD
Methylnaltrexone—Nervous system disorder—Doxorubicin—prostate cancer	0.000519	0.00122	CcSEcCtD
Methylnaltrexone—Skin disorder—Doxorubicin—prostate cancer	0.000514	0.00121	CcSEcCtD
Methylnaltrexone—Hyperhidrosis—Doxorubicin—prostate cancer	0.000511	0.00121	CcSEcCtD
Methylnaltrexone—Nausea—Docetaxel—prostate cancer	0.000504	0.00119	CcSEcCtD
Methylnaltrexone—Diarrhoea—Prednisone—prostate cancer	0.0005	0.00118	CcSEcCtD
Methylnaltrexone—Gastrointestinal disorder—Epirubicin—prostate cancer	0.000494	0.00116	CcSEcCtD
Methylnaltrexone—Pain—Epirubicin—prostate cancer	0.000489	0.00115	CcSEcCtD
Methylnaltrexone—Nausea—Capecitabine—prostate cancer	0.000488	0.00115	CcSEcCtD
Methylnaltrexone—Dizziness—Prednisone—prostate cancer	0.000483	0.00114	CcSEcCtD
Methylnaltrexone—Gastrointestinal pain—Epirubicin—prostate cancer	0.000468	0.0011	CcSEcCtD
Methylnaltrexone—Vomiting—Prednisone—prostate cancer	0.000465	0.0011	CcSEcCtD
Methylnaltrexone—Gastrointestinal disorder—Doxorubicin—prostate cancer	0.000457	0.00108	CcSEcCtD
Methylnaltrexone—Pain—Doxorubicin—prostate cancer	0.000452	0.00107	CcSEcCtD
Methylnaltrexone—Abdominal pain—Epirubicin—prostate cancer	0.000452	0.00107	CcSEcCtD
Methylnaltrexone—Nausea—Prednisone—prostate cancer	0.000434	0.00102	CcSEcCtD
Methylnaltrexone—Gastrointestinal pain—Doxorubicin—prostate cancer	0.000433	0.00102	CcSEcCtD
Methylnaltrexone—Abdominal pain—Doxorubicin—prostate cancer	0.000418	0.000986	CcSEcCtD
Methylnaltrexone—Diarrhoea—Epirubicin—prostate cancer	0.000391	0.000922	CcSEcCtD
Methylnaltrexone—Dizziness—Epirubicin—prostate cancer	0.000378	0.000891	CcSEcCtD
Methylnaltrexone—Vomiting—Epirubicin—prostate cancer	0.000364	0.000857	CcSEcCtD
Methylnaltrexone—Diarrhoea—Doxorubicin—prostate cancer	0.000362	0.000853	CcSEcCtD
Methylnaltrexone—Dizziness—Doxorubicin—prostate cancer	0.00035	0.000825	CcSEcCtD
Methylnaltrexone—Nausea—Epirubicin—prostate cancer	0.00034	0.0008	CcSEcCtD
Methylnaltrexone—Vomiting—Doxorubicin—prostate cancer	0.000336	0.000793	CcSEcCtD
Methylnaltrexone—Nausea—Doxorubicin—prostate cancer	0.000314	0.000741	CcSEcCtD
Methylnaltrexone—OPRK1—Signaling Pathways—CALCA—prostate cancer	6.77e-05	0.000342	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—TNFRSF21—prostate cancer	6.61e-05	0.000334	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—CXCL12—prostate cancer	6.61e-05	0.000334	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—PTHLH—prostate cancer	6.5e-05	0.000328	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—TGFBR1—prostate cancer	6.5e-05	0.000328	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—CYP7B1—prostate cancer	6.43e-05	0.000325	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—MTAP—prostate cancer	6.43e-05	0.000325	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—AKR1C3—prostate cancer	6.39e-05	0.000323	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—PRKACB—prostate cancer	6.36e-05	0.000321	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—PIK3CG—prostate cancer	6.3e-05	0.000318	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—SULT1E1—prostate cancer	6.27e-05	0.000317	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—SRD5A1—prostate cancer	6.27e-05	0.000317	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—CASP9—prostate cancer	6.22e-05	0.000314	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—PPP3CA—prostate cancer	6.2e-05	0.000313	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—THBS1—prostate cancer	6.2e-05	0.000313	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—ANXA1—prostate cancer	6.11e-05	0.000309	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR downstream signaling—PIK3CD—prostate cancer	6.1e-05	0.000308	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—PRKCQ—prostate cancer	6.03e-05	0.000305	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—NGFR—prostate cancer	6.03e-05	0.000305	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—PRKCZ—prostate cancer	6e-05	0.000303	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—HSD17B3—prostate cancer	5.98e-05	0.000302	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—ACSL4—prostate cancer	5.98e-05	0.000302	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—MAP3K7—prostate cancer	5.96e-05	0.000301	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR downstream signaling—PIK3CG—prostate cancer	5.86e-05	0.000296	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—PARP1—prostate cancer	5.79e-05	0.000292	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—FGFR4—prostate cancer	5.79e-05	0.000292	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—ARG2—prostate cancer	5.73e-05	0.00029	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—UMPS—prostate cancer	5.73e-05	0.00029	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—PHGDH—prostate cancer	5.73e-05	0.00029	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—FGF10—prostate cancer	5.73e-05	0.000289	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—CALCA—prostate cancer	5.72e-05	0.000289	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—ADRB2—prostate cancer	5.67e-05	0.000286	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—LDHB—prostate cancer	5.62e-05	0.000284	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR downstream signaling—JAK2—prostate cancer	5.59e-05	0.000283	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—CXCL12—prostate cancer	5.59e-05	0.000282	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—MAP2K1—prostate cancer	5.57e-05	0.000281	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—PIK3CD—prostate cancer	5.54e-05	0.00028	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—VAV3—prostate cancer	5.53e-05	0.000279	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—CYP3A5—prostate cancer	5.52e-05	0.000279	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—TGFBR2—prostate cancer	5.45e-05	0.000275	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—ITPR1—prostate cancer	5.36e-05	0.000271	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—PDHA1—prostate cancer	5.33e-05	0.000269	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—GSTA3—prostate cancer	5.33e-05	0.000269	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—UCP3—prostate cancer	5.33e-05	0.000269	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—TCN2—prostate cancer	5.33e-05	0.000269	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—PIK3CG—prostate cancer	5.32e-05	0.000269	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR downstream signaling—PIK3CB—prostate cancer	5.31e-05	0.000268	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—CASP9—prostate cancer	5.26e-05	0.000266	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR downstream signaling—PIK3CD—prostate cancer	5.15e-05	0.00026	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—IGF1R—prostate cancer	5.13e-05	0.000259	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR downstream signaling—CXCL8—prostate cancer	5.11e-05	0.000258	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—NGFR—prostate cancer	5.1e-05	0.000257	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—PRKCQ—prostate cancer	5.1e-05	0.000257	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—HSD3B1—prostate cancer	5.08e-05	0.000257	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—SLC22A3—prostate cancer	5.08e-05	0.000257	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—JAK2—prostate cancer	5.08e-05	0.000257	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—MAP3K7—prostate cancer	5.04e-05	0.000254	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—LPL—prostate cancer	4.92e-05	0.000248	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR downstream signaling—IL2—prostate cancer	4.88e-05	0.000246	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—GSTA4—prostate cancer	4.87e-05	0.000246	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—TBXAS1—prostate cancer	4.87e-05	0.000246	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—PDGFRB—prostate cancer	4.87e-05	0.000246	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—FGF10—prostate cancer	4.84e-05	0.000245	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—PIK3CB—prostate cancer	4.82e-05	0.000244	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—ADRB2—prostate cancer	4.79e-05	0.000242	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—GSTA2—prostate cancer	4.75e-05	0.00024	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—ITGB3—prostate cancer	4.75e-05	0.00024	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR downstream signaling—JAK2—prostate cancer	4.73e-05	0.000239	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—MAP2K1—prostate cancer	4.71e-05	0.000238	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—SULT1A1—prostate cancer	4.69e-05	0.000237	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—ABCG5—prostate cancer	4.69e-05	0.000237	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—PIK3CD—prostate cancer	4.68e-05	0.000236	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—VAV3—prostate cancer	4.67e-05	0.000236	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—CXCL8—prostate cancer	4.64e-05	0.000234	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—TGFBR2—prostate cancer	4.61e-05	0.000233	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—ERBB3—prostate cancer	4.61e-05	0.000233	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—FGFR2—prostate cancer	4.6e-05	0.000232	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—GSTA1—prostate cancer	4.58e-05	0.000232	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—ITPR1—prostate cancer	4.53e-05	0.000229	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—GSTO1—prostate cancer	4.53e-05	0.000229	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—HSD3B2—prostate cancer	4.53e-05	0.000229	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—NAT2—prostate cancer	4.53e-05	0.000229	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR downstream signaling—PIK3CB—prostate cancer	4.49e-05	0.000227	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—IL2—prostate cancer	4.43e-05	0.000224	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—TERT—prostate cancer	4.41e-05	0.000223	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—PLCB2—prostate cancer	4.34e-05	0.000219	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—LRP2—prostate cancer	4.34e-05	0.000219	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—CYP2C18—prostate cancer	4.34e-05	0.000219	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—IGF1R—prostate cancer	4.33e-05	0.000219	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR downstream signaling—CXCL8—prostate cancer	4.32e-05	0.000218	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—JAK2—prostate cancer	4.29e-05	0.000217	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—P4HB—prostate cancer	4.26e-05	0.000215	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—HIF1A—prostate cancer	4.22e-05	0.000213	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—LPL—prostate cancer	4.16e-05	0.00021	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—SLC22A1—prostate cancer	4.14e-05	0.000209	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR downstream signaling—IL2—prostate cancer	4.12e-05	0.000208	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—LEP—prostate cancer	4.12e-05	0.000208	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—PDGFRB—prostate cancer	4.12e-05	0.000208	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—CAV1—prostate cancer	4.08e-05	0.000206	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—PIK3CB—prostate cancer	4.08e-05	0.000206	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—SULT2A1—prostate cancer	4.04e-05	0.000204	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—KDR—prostate cancer	4.04e-05	0.000204	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—ITGB3—prostate cancer	4.01e-05	0.000203	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—MED12—prostate cancer	3.97e-05	0.000201	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—GNG5—prostate cancer	3.94e-05	0.000199	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—ESR1—prostate cancer	3.93e-05	0.000199	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—CXCL8—prostate cancer	3.92e-05	0.000198	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—ERBB3—prostate cancer	3.89e-05	0.000197	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—FGFR2—prostate cancer	3.89e-05	0.000196	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—BAD—prostate cancer	3.84e-05	0.000194	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—NCOA3—prostate cancer	3.8e-05	0.000192	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—IL2—prostate cancer	3.74e-05	0.000189	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—TERT—prostate cancer	3.73e-05	0.000188	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—APC—prostate cancer	3.72e-05	0.000188	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—PIK3CG—prostate cancer	3.72e-05	0.000188	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—EGF—prostate cancer	3.68e-05	0.000186	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—IRS1—prostate cancer	3.68e-05	0.000186	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—HPGDS—prostate cancer	3.62e-05	0.000183	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—CYP2C19—prostate cancer	3.6e-05	0.000182	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—GSK3B—prostate cancer	3.57e-05	0.00018	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—HIF1A—prostate cancer	3.57e-05	0.00018	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—INS—prostate cancer	3.52e-05	0.000178	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—ACHE—prostate cancer	3.51e-05	0.000177	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—GSTT1—prostate cancer	3.51e-05	0.000177	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—LEP—prostate cancer	3.48e-05	0.000176	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—CYP2A6—prostate cancer	3.47e-05	0.000175	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—CAV1—prostate cancer	3.45e-05	0.000174	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—CREBBP—prostate cancer	3.45e-05	0.000174	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—KDR—prostate cancer	3.41e-05	0.000172	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—IGF1—prostate cancer	3.41e-05	0.000172	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—EGFR—prostate cancer	3.39e-05	0.000171	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—AKR1C3—prostate cancer	3.38e-05	0.000171	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—PRKACB—prostate cancer	3.36e-05	0.00017	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—CYP17A1—prostate cancer	3.33e-05	0.000168	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—ESR1—prostate cancer	3.33e-05	0.000168	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—MAP2K1—prostate cancer	3.29e-05	0.000166	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—PIK3CD—prostate cancer	3.27e-05	0.000165	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—BAD—prostate cancer	3.25e-05	0.000164	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR downstream signaling—PIK3CA—prostate cancer	3.24e-05	0.000164	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—SERPINE1—prostate cancer	3.23e-05	0.000163	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—KRAS—prostate cancer	3.2e-05	0.000162	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—NCOA2—prostate cancer	3.17e-05	0.00016	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—APC—prostate cancer	3.14e-05	0.000159	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—PIK3CG—prostate cancer	3.14e-05	0.000159	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—FGF2—prostate cancer	3.13e-05	0.000158	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—EGF—prostate cancer	3.11e-05	0.000157	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—IRS1—prostate cancer	3.11e-05	0.000157	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—NOS3—prostate cancer	3.09e-05	0.000156	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—SLC5A5—prostate cancer	3.02e-05	0.000153	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—GSK3B—prostate cancer	3.02e-05	0.000152	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—JAK2—prostate cancer	3e-05	0.000152	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—INS—prostate cancer	2.98e-05	0.00015	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—CYP2E1—prostate cancer	2.95e-05	0.000149	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—PIK3CA—prostate cancer	2.94e-05	0.000149	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—MDM2—prostate cancer	2.93e-05	0.000148	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—NQO1—prostate cancer	2.92e-05	0.000148	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—CREBBP—prostate cancer	2.91e-05	0.000147	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—ERBB2—prostate cancer	2.89e-05	0.000146	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—IGF1—prostate cancer	2.88e-05	0.000145	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—TH—prostate cancer	2.88e-05	0.000145	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—EGFR—prostate cancer	2.86e-05	0.000145	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—PIK3CB—prostate cancer	2.85e-05	0.000144	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—CYP3A4—prostate cancer	2.85e-05	0.000144	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—CYP1B1—prostate cancer	2.8e-05	0.000141	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—MAP2K1—prostate cancer	2.78e-05	0.000141	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—PIK3CD—prostate cancer	2.76e-05	0.00014	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—CXCL8—prostate cancer	2.74e-05	0.000138	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR downstream signaling—PIK3CA—prostate cancer	2.74e-05	0.000138	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—SERPINE1—prostate cancer	2.73e-05	0.000138	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—GGT1—prostate cancer	2.71e-05	0.000137	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—KRAS—prostate cancer	2.71e-05	0.000137	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—CDKN1B—prostate cancer	2.67e-05	0.000135	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—NCOA1—prostate cancer	2.67e-05	0.000135	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—FGF2—prostate cancer	2.65e-05	0.000134	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR downstream signaling—AKT1—prostate cancer	2.65e-05	0.000134	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—CYP19A1—prostate cancer	2.63e-05	0.000133	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—CASP3—prostate cancer	2.62e-05	0.000132	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—IL2—prostate cancer	2.62e-05	0.000132	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—NOS3—prostate cancer	2.61e-05	0.000132	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—IL6—prostate cancer	2.6e-05	0.000132	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—CCND1—prostate cancer	2.55e-05	0.000129	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—RXRA—prostate cancer	2.54e-05	0.000128	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—JAK2—prostate cancer	2.54e-05	0.000128	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—CTNNB1—prostate cancer	2.53e-05	0.000128	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—PIK3CA—prostate cancer	2.49e-05	0.000126	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—MMP9—prostate cancer	2.48e-05	0.000125	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—MDM2—prostate cancer	2.48e-05	0.000125	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—CDKN1A—prostate cancer	2.47e-05	0.000125	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—PTEN—prostate cancer	2.46e-05	0.000124	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—COMT—prostate cancer	2.45e-05	0.000124	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—ERBB2—prostate cancer	2.44e-05	0.000123	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—GSTP1—prostate cancer	2.44e-05	0.000123	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—PIK3CB—prostate cancer	2.41e-05	0.000122	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—AKT1—prostate cancer	2.4e-05	0.000121	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—ITPR1—prostate cancer	2.4e-05	0.000121	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—EP300—prostate cancer	2.35e-05	0.000119	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—CXCL8—prostate cancer	2.31e-05	0.000117	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—SRC—prostate cancer	2.28e-05	0.000115	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—TYMS—prostate cancer	2.26e-05	0.000114	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—CDKN1B—prostate cancer	2.26e-05	0.000114	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—GSTM1—prostate cancer	2.24e-05	0.000113	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR downstream signaling—AKT1—prostate cancer	2.24e-05	0.000113	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—VEGFA—prostate cancer	2.22e-05	0.000112	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—CASP3—prostate cancer	2.22e-05	0.000112	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—IL2—prostate cancer	2.21e-05	0.000112	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—STAT3—prostate cancer	2.2e-05	0.000111	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—IL6—prostate cancer	2.2e-05	0.000111	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—LPL—prostate cancer	2.2e-05	0.000111	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—CCND1—prostate cancer	2.16e-05	0.000109	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—CTNNB1—prostate cancer	2.14e-05	0.000108	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—CYP1A1—prostate cancer	2.12e-05	0.000107	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—ERCC2—prostate cancer	2.1e-05	0.000106	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—MMP9—prostate cancer	2.09e-05	0.000106	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—CDKN1A—prostate cancer	2.09e-05	0.000105	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—PTEN—prostate cancer	2.08e-05	0.000105	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—MYC—prostate cancer	2.05e-05	0.000103	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—TGFB1—prostate cancer	2.04e-05	0.000103	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—AKT1—prostate cancer	2.03e-05	0.000103	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—EGFR—prostate cancer	2e-05	0.000101	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—EP300—prostate cancer	1.99e-05	0.0001	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—MTHFR—prostate cancer	1.98e-05	9.99e-05	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—PPARA—prostate cancer	1.94e-05	9.8e-05	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—SRC—prostate cancer	1.93e-05	9.75e-05	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—KRAS—prostate cancer	1.89e-05	9.55e-05	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—VEGFA—prostate cancer	1.88e-05	9.5e-05	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—STAT3—prostate cancer	1.86e-05	9.4e-05	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—CAV1—prostate cancer	1.82e-05	9.22e-05	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—PIK3CA—prostate cancer	1.74e-05	8.78e-05	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—MYC—prostate cancer	1.73e-05	8.74e-05	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—TGFB1—prostate cancer	1.73e-05	8.72e-05	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—EGFR—prostate cancer	1.69e-05	8.55e-05	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—TP53—prostate cancer	1.68e-05	8.49e-05	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—PIK3CG—prostate cancer	1.66e-05	8.39e-05	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—KRAS—prostate cancer	1.6e-05	8.07e-05	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—INS—prostate cancer	1.57e-05	7.95e-05	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—CREBBP—prostate cancer	1.54e-05	7.78e-05	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—IL6—prostate cancer	1.54e-05	7.77e-05	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—PIK3CA—prostate cancer	1.47e-05	7.42e-05	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—PIK3CD—prostate cancer	1.46e-05	7.38e-05	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—TP53—prostate cancer	1.42e-05	7.18e-05	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—AKT1—prostate cancer	1.42e-05	7.17e-05	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—NOS3—prostate cancer	1.38e-05	6.97e-05	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—IL6—prostate cancer	1.3e-05	6.57e-05	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—PIK3CB—prostate cancer	1.27e-05	6.43e-05	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—PTGS2—prostate cancer	1.26e-05	6.37e-05	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—AKT1—prostate cancer	1.2e-05	6.06e-05	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—PTEN—prostate cancer	1.1e-05	5.56e-05	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—EP300—prostate cancer	1.05e-05	5.3e-05	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—PIK3CA—prostate cancer	7.76e-06	3.92e-05	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—AKT1—prostate cancer	6.34e-06	3.2e-05	CbGpPWpGaD
